From: Tumor-related interleukins: old validated targets for new anti-cancer drug development
Class | Drug | Effects | Clinical trials | Ref. |
---|---|---|---|---|
Targeting signaling | Ruxolitinib leflunomide | Inhibition of JAK1/2 resulting in STAT6 phosphorylation inhibition Inhibition of STAT6 Phosphorylation | FDA approved for myelofibrosis. Phase I/II trials for CML, AML, colorectal cancer, NSCLC, lung adenocarcinoma, and breast cancer in preparation. Approved for RA treatment, immunosuppressive therapy after organ transplantation | |
Blocking IL-4/IL-4R interaction | Dupilumab AMG317 Pitrakinra Altrakincept Pascolizumab | Humanized anti–IL-4Rα mAb Humanized anti–IL-4Rα mAb modified form of IL4 Recombinant human IL4R Humanized anti–IL4 (IgG1) Antibody | Phase III trials for asthma and atopic dermatitis are ongoing Good results of Phase I/II trials in asthma then abandoned due to lack of efficacy Completed phase I/II/III trials in asthma. Abandoned after Phase I/II trials completion for asthma due to lack of efficacy Abandoned after Phase I/II trials completion for asthma due to lack of efficacy | [185] [202] |